First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
Scientists pinpoint a skin alarm system pathway that links local damage to systemic immune responses
Skin, our largest organ, acts as a protective barrier against pathogens that try to invade our bodies while constantly monitoring for potential threats. In the skin's outermost layer, the epidermis, ...
Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...
A study published in Nature Medicine identified a link between the placebo effect and immune system function. In the experiment, individuals who generated positive expectations showed a stronger ...
Scientists have long observed that cancer patients have a lower risk of Alzheimer’s disease. New research reveals a possible reason why. These brain scans of a 74-year-old patient with Alzheimer's ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...
Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...
A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas Eve regulatory ...
Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...
In 2022, a man with disabilities was found dead in the woods. The state was supposed to protect him.
This story was originally produced by the New Hampshire Bulletin, an independent local newsroom that allows NHPR and other outlets to republish its reporting. This is the second in a three-part series ...
The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results